| Autor: |
Glode, Ashley E., Jarkowski III, Anthony |
| Předmět: |
|
| Zdroj: |
Pharmacotherapy; Nov2009, Vol. 29 Issue 11, p1375-1384, 10p, 1 Diagram, 7 Charts |
| Abstrakt: |
Chronic lymphocytic leukemia (CLL) is a slow-growing hematologic malignancy and the most common type of leukemia in the western world. The lifetime risk for developing CLL is 1 in 216 men and women. Unfortunately, CLL is considered incurable with the chemotherapeutic agents available today. Bendamustine is a new agent that was recently added to the available regimens for the treatment of CLL. It was also recently approved for the treatment of non-Hodgkin's lymphoma. Its mechanism of action is unknown, but it contains an alkylating group similar to that of other bifunctional alkylating agents such as chlorambucil, and it also contains a benzimidazole central ring thought to exhibit antipurine-like properties. The United States Food and Drug Administration approved bendamustine based on results from an international phase III study of CLL in which bendamustine was compared with chlorambucil in treatment-naive patients. Ongoing clinical trials are assessing the utility of bendamustine in combination with other agents for the treatment of CLL, as well as for other malignancies. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text